Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Curium's ECLIPSE Trial Meets Endpoint for PSMA-Positive Prostate Cancer Patients
Details : Lutetium (177Lu) Zadavotide Guraxetan is a novel treatment for mCRPC following the failure of traditional treatments, works by emitting beta radiations and modulating PSMA.
Product Name : PNT2002
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
November 13, 2024
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
Details : Lutetium Lu 177 Dotatate is an IV, SSRT2 inhibitor, radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Product Name : Undisclosed
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
September 07, 2024
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
Details : No supply challenges of Lu-177-PSMA for the Phase 3 ECLIPSE clinical trial (NCT05204927), evaluating Lutetium 177LuPSMA-I&T treatment compared to the standard of care hormone therapy in men with metastatic Castration-Resistant Prostate Cancer.
Product Name : 177-Lu PSMA-I&T
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
December 05, 2022
Curium’s Phase 3 ECLIPSE Trial Starts Enrolling Patients
Details : ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer.
Product Name : 177-Lu PSMA-I&T
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
March 05, 2022